SCYX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
SCYX 近期報酬表現
6.64%
Scynexis inc
2.35%
同產業平均
-0.21%
S&P500
與 SCYX 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
MURA | Mural oncology plc | - | 2 分 | - | - | 1 分 | |
ARCT | Arcturus therapeutics holdings inc | 3 分 | 3 分 | 5 分 | 3 分 | 1 分 | |
PACB | Pacific biosciences of california inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
ESLA | Estrella immunopharma inc | - | 2 分 | 2 分 | - | 1 分 | |
ACHV | Achieve life sciences inc | 3 分 | 5 分 | 2 分 | 1 分 | 1 分 |
- MURA Mural oncology plc價值 -趨勢 2 分波段 -籌碼 -股利 1 分查看更多
SCYX 公司資訊
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.